

PRODUCT PORTFOLIO



Excellence through EU GMP-Approved facility

Trusted manufacturer of CEP-grade Metformin HCl, Gliclazide with global regulatory compliance for API, DC Granules and Pellets Facility.



End-to-End Solutions

From API to DC Granules to Finished Formulations -complete vertical integration for superior quality control.



Quality You Can Trust

Delivering consistent, high quality API, DC Granules and Pellets that exceed industry standards.



Robust Product Development

We specialize in developing pharmaceutically equivalent and bioequivalent products, backed by eCTD-compliant dossiers.



Specialized CDMO Approach

A distinctive CDMO model offering flexible, customized solutions tailored to individual client needs.

Active Pharmaceutical Ingredients (APIs)

Product	Therapeutic Category	Regulatory Credentials	
		CEP	DMF For RoW
CEP/DMF Registered Products			
Metformin HCl USP/EP/BP/JP/IP	Anti-Diabetics	✓	✓
Gliclazide EP/BP/IP	Anti-Diabetics	✓	✓
Folic Acid USP/EP/BP/IP	Vitamin	CEP Filed	✓
Dapagliflozin USP/EP/IP/IH	Anti-Diabetics	CEP Filed	✓
Rebamipide IH/JP	Anti-Ulcer	JDMF Filed	✓
Alogliptin Benzoate IH	Anti-Diabetics		✓

Near-Term Pipeline

Product Name	Therapeutic Category	Availability
Imeglimin HCl IH	Anti-Diabetics	In Pipeline (Q1 2027)
Empagliflozin IH	Anti-Diabetics	Pipeline (Q4 2026)
Sitagliptin Phosphate USP/EP/BP/IP	Anti-Diabetics	Teckpack Available
Isosorbide	Anti-Anginal	Q4 2027
Isosorbide Dimethyl	Anti-Anginal	Q4 2027
Isosorbide Dinitrate 10 %, 20%, 25%, 40%	Anti-Anginal	Q4 2027
Isosorbide Mononitrate 20 %, 40 %, 50 %, 60%, 70%, 80%, 90%	Anti-Anginal	Q4 2027
Chlorzoxazone	Muscle Relaxant	Q4 2027

Semi Finished Formulation (DC Granules)

Product	Therapeutic Category	Regulatory Status
Metformin HCl DC - IR 83.33%, 86.6%, 90%, 93.6%, & 95% w/w	Anti-Diabetics	DMF Available
Metformin HCl DC - XR 69.44%, 73.53%, 77.52% w/w	Anti-Diabetics	DMF Available
Methocarbamol DC 90% w/w	Pain Medication	DMF Available
Gliclazide MR DC 18.75% w/w	Anti-Diabetics	DMF under Compilation
Dapagliflozin DC 5% w/w	Anti-Diabetics	R&D Developed

Finished Dosage Formulation (FDF)

Product	Dosage Form	RLD	Marketing Authorisations
Metformin XR 500mg, 750mg, 1000mg	Prolonged release tablets	Glucophage SR (Merck Serono Ltd, UK)	MA in UK, Germany, Poland, Bulgaria & filed-Emerging markets
Dapagliflozin 5mg, 10mg	Film coated tablets	Forxiga (AstraZeneca AB, Sweden)	Filed in UK, Sweden, Germany & Greece
Topiramate 15mg, 25mg, 50mg	Sprinkle capsules	Topamax (Janssen- Cilag B.V, Netherlands)	Filed in UK, Portugal
Dapagliflozin, Metformin IR 5mg,850mg; 5mg,1gm	Film coated tablets	Xigduo AstraZeneca AB, Sweden	Filed in UK, Germany, Ireland
Gliclazide MR 30 mg, 60 mg	Modified release tablets	Diamicron LM MR (Les Laboratories Servier, France)	Dossier by Q4 2026
Dapagliflozin, Metformin XR 5mg, 500mg; 5mg, 1gm;10mg, 500mg; 10mg, 1gm	Modified release tablets	Xigduo XR (AstraZeneca AB, Australia)	Dossier by Q1 2027
Empagliflozin 10 mg, 25 mg	Film coated tablets	Jardiance (Boehringer Ingelheim GmbH, Germany)	Dossier by Q1 2027
Empagliflozin, Metformin 5mg, 500mg; 5mg, 1gm; 12.5mg, 500mg; 12.5mg, 1gm	Film coated tablets	Synjardy (Boehringer Ingelheim GmbH, Germany)	Dossier by Q1 2027
Sitagliptin, Metformin XR 50mg, 500mg; 50mg, 1gm; 100mg, 1gm	Modified release tablets	Janumet XR(MSD LLC, USA) & Simedur (Teva, Portugal)	Dossier by Q1 2027
Empagliflozin, Metformin XR 5mg, 1gm; 10mg, 1gm; 12.5mg, 1gm	Modified release tablets	Synjardy XR, Boehringer Ingelheim	Dossier by Q2 2027
Lansoprazole Capsules 15 mg & 30 mg	Delayed release capsules	Agopton – Takeda Germany	Dossier by Q3 2027

Pipeline Product

Generic Name	Dosage Form	RLD
Mesalamine 250 mg, 500 mg	Extended-release Capsules	Pentasa - Ferring Pharmaceuticals A/S (Denmark)
Naproxene + Paracetamol 325 mg + 110 mg	Immediate-release Tablets	Tylenol with Naproxen - Kenvue Brands LLC (USA)
Naproxene + Esomeprazole 500 mg + 20 mg / 375mg + 20mg	Modified-release Tablets	Vimovo – AstraZeneca (Netherlands)
Esomeprazole 20 mg, 40 mg	Gastro resistant Capsule/ Tablets (MUPS)	Nexium Capsules / Tablets (AstraZeneca AB, Sweden)
Esomeprazole Sachet 10 mg	Delayed-release Granules	Nexium Sachet - Grünenthal B.V. (Netherlands) Nexium - AstraZeneca (UK)
Tamsulosin + Dutasteride 0.4 mg + 0.5mg	Modified-release Capsules	Duodart / Combodart - GlaxoSmithKline (Europe)
Tamsulosin 0.4 mg	Modified-release Capsules	Omnice / Flomax - Astellas Pharma (NL)
Mirabegron 25 mg, 50 mg	Extended-release Tablets	Betmiga - Astellas Pharma Europe B.V. (Europe)
Mirabegron + Solifenacin 25 mg + 5 mg,50 mg + 5 mg	Extended-release Tablets	Betmiga + VESicare - Astellas Pharma (Europe)
Bempedoic acid + Ezetimibe 180 mg + 10mg	Film-coated Tablets	Nustendi - Daiichi Sankyo Europe GmbH (Germany)
Quetiapine 50 mg, 200 mg,300 mg, 400 mg	Extended-release Tablets	Seroquel XR / Seroquel Prolong - AstraZeneca UK Limited (UK)
Ursodeoxycholic acid (Ursodiol) Tablets 250, 300, 500 mg	Film-coated Tablets	Ursofalk - Dr.Falk Pharma, Germany
Melatonin 2 mg	Prolonged-release Tablets	Circadin - Neurim Pharmaceuticals (Europe)

Pre Finished Formulation Intermediates (PFIs)

Product	Therapeutic Category	Regulatory Status
Orlistat IR Pellets (IHS,USP) 50% w/w	Anti-Obesity	DMF Available
Esomeprazole EC Pellets/MUPS 8.5%, 13.75%*, 22.5% w/w	Proton Pump Inhibitor	DMF under Execution
Fenofibrate Pellets 66.234% w/w	Lipid Modifying agent	DMF Available
Topiramate Sprinkle Pellets 22.32% w/w	Anti-Convulsant	DMF Available
Metoprolol Succinate ER Pellets** 62% w/w	Anti-Hypertensive	DMF under Execution
Itraconazole Pellets 22% w/w	Anti-Fungal	DMF by Dec'2026
Omeprazole EC Pellets 8.5% w/w	Proton Pump Inhibitor	DMF by Dec'2026
Lansoprazole EC Pellets/MUPS 8.5% w/w	Proton Pump Inhibitor	DMF by Dec'2026
Dexlansoprazole DDR Pellets 17%, 20%, 22.5%, 23% w/w	Proton Pump Inhibitor	DMF by Dec'2026
Fenofibric Acid Pellets 29% w/w	Lipid Modifying agent	R&D Developed
Tamsulosin HCl SR Pellets 0.125%, 0.2% w/w	Alpha-Blockers	Under Development
Tamsulosin HCl SR Pellets (0.4 mg)+ Dutasteride IR Pellets (0.5 mg)	Alpha-Blockers	Under Development
Duloxetine Pellets 17%, 20% w/w	Anti-Depressant	Under Development
Venlafaxine Pellets 32%, 33%w/w	Anti-Depressant	Under Development
Mebeverine Pellets 76%, 80% w/w	Anti-Cholinergic	Under Development
Mesalamine SR Pellets 70%, 90%, 96.38% w/w	Anti-Inflammatory	Under Development

*CDMO product, exclusively manufacturing for our customer

**CDMO product, exclusive for Korea market, other markets are open

Products which are subject to patent protection are currently not offered or made available where patents are in force

Corporate Address

7110, 7120, Marvel Fuego,
Magarpatta Road, Opp. Seasons Mall,
Hadapsar, Pune – 411028 ,
Maharashtra, India

Contact Details

Phone No.: +91 (20) 26890771

Factory Address

D 30, Kurkumbh, MIDC, Tal Daund,
Dist Pune 413802, Maharashtra
India

Email

marktg@sohanhealthcare.com

